The purpose of such a Phase 1 clinical trial is to assess safety, so problems wouldnâ€™t come as a total shock. The fact that the trial in cancer patients (which still needs OKs from the Food and Drug Administration, among others) would be funded by the new cancer institute founded this year by tech mogul Sean Parker adds a wild card. Four potential snafus: